What is uFraction8?
Founded in 2017 and headquartered in Falkirk, Scotland, uFraction8 is at the forefront of developing advanced microfluidics-based filtration systems. The company's proprietary technology harnesses hydrodynamic phenomena to offer an energy-efficient and scalable alternative to conventional filtration methods, including filters, membranes, flocculants, and centrifuges. This innovation is particularly impactful for the biopharmaceutical, food, and bio-based product industries, aiming to optimize downstream processing and reduce operational expenditures. uFraction8's approach addresses critical needs for efficiency and sustainability in modern biomanufacturing.
How much funding has uFraction8 raised?
uFraction8 has raised a total of $7.7M across 2 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$4.3M
Other Financing Round (2022): $3.4M, investors not publicly disclosed
Other Financing Round (2025): $4.3M led by Alwyn Capital, Thia Ventures, Foresight Group, Scottish Enterprise, Old College Capital, and The University of Edinburgh
Key Investors in uFraction8
Alwyn Capital
Alwyn Capital is an early-stage venture fund backing the next generation of biotech companies committed to developing solutions that mitigate worldwide reliance on animals - a strategic imperative in tackling both climate and human health issues.
Thia Ventures
Thia Ventures is a fund management company that focuses on investments at the intersection of food, biotechnology, and health. Managed by Eightstone Pte Ltd, it operates under a Capital Markets Services license in Singapore. The company aims to support innovative ventures that combine these sectors to drive growth and development.
Foresight Group
Founded in 1984, Foresight Group is a leading independent infrastructure and private equity investment manager. The company is headquartered in London, United Kingdom.
What's next for uFraction8?
The recent major strategic investment in uFraction8 positions the company for accelerated expansion and technological advancement. With a focus on enhancing biomanufacturing efficiency, this capital injection is likely to fuel further research and development, market penetration, and the scaling of production capabilities. The company's commitment to providing sustainable and cost-effective filtration solutions suggests a strategic trajectory aimed at capturing a larger share of the global bioprocessing market. Future developments may include broader industry adoption and the introduction of next-generation microfluidic technologies.
See full uFraction8 company page
